Upstream Bio raises funds to advance clinical development of UPB-101

09 Jun 2023
www.pharmaceutical-technology.com
Gene TherapyPhase 1Phase 2IND
Upstream Bio raises funds to advance clinical development of UPB-101
Preview
Source: Pharmaceutical Technology
Upstream Bio’s UPB-101 addresses allergic and inflammatory diseases, including asthma. Credit: natatravel via Shutterstock.com.
Clinical-stage biotech company Upstream Bio has raised $200m in a Series B financing round to advance its UPB-101 to treat allergic and inflammatory diseases.
Co-led by Venrock Healthcare Capital Partners (Venrock) and Enavate Sciences, the financing round has seen participation from new investors Wellington Management and Bain Capital Life Sciences.
Recommended Reports
Upstream Bio raises funds to advance clinical development of UPB-101
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene Therapy to Target KK-LC-1 for Oncology GlobalData
Upstream Bio raises funds to advance clinical development of UPB-101
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene Therapy to Target CEA for Oncology GlobalData
View all
Series A investors Omega Funds, Altshuler Shaham Provident Funds, Access Biotechnology, Samsara BioCapital, TCG X, OrbiMed, Decheng Capital and HBM Healthcare Investments have also participated in the financing round.
Upstream Bio will use the funds to advance its UPB-101 into Phase II trials to treat asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
It is also preparing for a swift transition to Phase III development.
A new recombinant fully human immunoglobulin G1 monoclonal antibody, UPB-101, is now being evaluated in a Phase 1b trial to treat asthma.
It targets the human thymic stromal lymphopoietin receptor to inhibit signalling.
The therapy showed that it can inhibit the production of cytokine from both CD4+ T cells and ILC2, and completely suppressed skin allergic reactions in a monkey model in pre-clinical trials.
Upstream Bio CEO Samantha Truex stated: “Our IND has been cleared by the FDA to pursue Phase II programmes in both asthma and CRSwNP.
“These studies are designed to generate evidence that targeting TSLPR may offer people suffering from asthma and CRSwNP a safe and effective therapy with the advantage of less frequent dosing.”
The company also announced that Enavate Sciences Commercialisation executive vice-president Dr Edd Fleming and Venrock partner Alex Rosen have joined its board of directors.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.